Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week phase 2b/3 trial of brazikumab versus placebo and Humira in moderate to severe Crohn's disease
MOH_2020-10-06_009384Phase 3Not yet recruiting
- Sponsor
- Allergan
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brazikumab in Crohn's disease (7 arms), sponsored by Allergan. Primary endpoints: Endoscopic response, Clinical remission and 2 more. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
brazikumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2020-10-06_009384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-06_009384.